initial diagnostic test were identified from a multicenter database using complete facility, physician and pharmacy data from two large health care plans from 2003-05. 1-year downstream CADrelated episodes of care were examined for patients after initial MDCT or MPI. Costs were further sub-classified by utilization of high-cost resources, including cardiac catheterization, percutaneous transluminal coronary angioplasty (PTCA), and coronary artery bypass surgery (CABG). RESULTS: A total of 18,489 patients underwent either MDCT (n = 638) or MPS (n = 17,851) testing during the study period. While costs per CAD-related episodes were similar between MDCT and MPS groups ($5,878 vs. $6,079, p = 0.20 The general objective of this study was to develop an explicit pharmacoeconomic threshold for purposes of pharmaceutical decision making in South Africa (SA).
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The general objective of this study was to develop an explicit pharmacoeconomic threshold for purposes of pharmaceutical decision making in South Africa (SA).
METHODS:
For the determination of a pharmacoeconomic threshold for pharmaceutical decision-making in SA, the method of the WHO, namely the "three-times-GDP per capita" approach, was used. To determine the GDP per capita for each health care sector, i.e. private and public, in SA it was needed to determine the income and number of people in each sector. The GDP for the public sector was calculated by dividing the income generated in the public sector by the total income generated in SA and then multiplying it by the total GDP (Total GDP according to Statistics South Africa in 2006 = R1,726,688,000,000 (US$ 246,700,000,000)). The same formula will be used to determine the GDP for the private sector. To determine the total income in each sector, data from the All Media Products Survey (AMPS) was used. 
PCV64 CLINICAL AND ECONOMIC IMPACT OF DRUG-ELUTING STENT AND BARE METAL STENT IN HONG KONG-A SINGLE CETRE "REAL WORLD" EXPERIENCE: AN INTERIM ANALYSIS
Lee VWY, Kum L, Lee T, Wong W,Yu C The Chinese University of Hong Kong, Shatin, Hong Kong OBJECTIVES: We aimed to evaluate the clinical outcome of BMS and DES placement in coronary artery disease patients and estimate the cost of BMS and DES placement in a Chinese population. METHODS: It was a retrospective cross-sectional study. We included all patients who underwent PCI with stent placement of either DES or BMS in a tertiary public hospital in Hong Kong over 4-month period. Patients were followed up for the occurrence of MACE within 12 months of the index stent placement. MACE was defined as cardiac death, non-fatal myocardial infarction and target lesion revascularization. Direct medical costs were estimated based on the procedural cost, hospitalization, medications, cardiac follow-up and repeated interventions taken. RESULTS: This interim analysis included 184 patients. Twelve-month MACE rate was 12.2% in BMS versus 3.4% in DES (p = 0.042). Rate of cardiac death was 3.7% in BMS versus 0% in DES group (p = 0.110). The mean 12-month cost per patient after index PCI was USD 8827.6 Ϯ 5634.0 (median = 7268.2) in DES and USD 7222.4 Ϯ 4538.1 (median = 6170.5) in BMS. On average, DES costs USD 1605.1 more than BMS per patient. CONCLUSION: Routine usage of DES is more costly than BMS that may discourage the use of DES in our public hospital setting. This may be explained by the less than expected difference in 12-month MACE between DES and BMS in our population and the lower hospitalization costs in Hong Kong. Further cost-effectiveness analysis will be conducted to evaluate the differences between DES and BMS. 3 SelectHealth Plans, Salt Lake City, UT, USA, 4 Blue Cross Blue Shield of Florida, Jacksonville, FL, USA OBJECTIVES: Dyslipidemia is a risk factor for coronary heart disease (CHD), which remains a leading cause of U.S. mortality, irrespective of sex, race/ethnicity, or age. Because the benefits of antilipidemics extend across patient characteristics, antilipidemic initiation rates should not widely vary by patient demographics. We conducted a large-scale retrospective claims analysis to confirm this assumption among newly-diagnosed adult dyslipidemic patients. METHODS: Nine-year (1997 Nine-year ( -2006 retrospective claims analysis of Florida Medicaid adults (Ն18 years) who had Ն1 year of data before and Ն3 years of data following their first dyslipidemia (ICD-9 272.X) diagnosis. Charlson Index classified disease burden. Logistic regression examined odds ratios. RESULTS: Among 231,110 dyslipidemic patients, 19,128 meeting eligibility criteria received antilipidemics during the index period; 18,346 did not. Women were 8% less likely to receive antilipidemics (OR 0.92, 95% CI 0.88-0.96, p = 0.0005) than men. Treatment initiation rates among Hispanics did not significantly differ from Whites. Blacks were 23% less likely (OR 0.77, 95% CI 0.73-0.81, p < 0.0001), and Other Ethnicities/ Races 17% more likely (OR 1.17, 95% CI 1.11-1.24, p < 0.0001) to receive antilipidemics during the follow-up period than Whites. Patients aged 50-64 years were 17% more likely (OR 1.17, 95% CI 1.10-1.25, p < 0.0001), and those aged Abstracts A425
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